1
Indications / Contraindications
Indications
- Recurrent malignant ascites: ovarian, hepatic, gastric, colorectal — patient undergoing ≥2 large-volume paracenteses per month
- Refractory non-malignant ascites: cirrhotic ascites failing maximal diuretic therapy requiring ≥2 LVP/month; palliative setting for terminal liver disease (median survival weeks–months)
- Malignant ascites with short life expectancy: avoids repeated hospitalizations/clinic visits
- Poor functional status: patient for whom repeated paracentesis procedures are not feasible
- Ovarian cancer with massive ascites causing respiratory compromise
Contraindications
- Active peritonitis or intraabdominal infection — treat infection first
- Multiloculated ascites where drainage of a single locule is unlikely to relieve symptoms — explicit CI from source (Ha et al. 2017)
- Coagulopathy: SIR 2019 thresholds for peritoneal drainage — INR <3.0, platelets >20K
- Multiple prior abdominal surgeries causing extensive adhesions — assess carefully with US; tethered bowel increases perforation risk
- Patient noncompliance — inability to perform or arrange home drainage
- Bowel obstruction or dilated bowel loops in planned access path
2
Pre-Procedure Checklist
CT abdomen/pelvis (if available): assess ascites distribution, loculations, bowel location, adhesion evidence, relationship to liver/spleen/bowel at planned access sites
Pre-procedure ultrasound: confirm free-flowing ascites in planned access site (LLQ standard), bowel-free window ≥3 cm
Labs: CBC, INR, BMP, albumin, total protein (baseline — serial monitoring required throughout dwell). SIR 2019 thresholds: INR <3.0, platelets >20K
Anticoagulation management: hold per SIR guidelines; DOACs hold 24–48h; warfarin hold 5 days
Consent: peritonitis/infection, protein/albumin loss (cachexia), electrolyte imbalances, catheter occlusion, bowel injury, exit site leakage (especially in cirrhotic patients), catheter fracture, need for removal. Complication rates similar to those with repeated LVP
Antibiotics: prophylactic antibiotics NOT demonstrated to reduce infection rate for tunneled peritoneal catheters (Rashid et al. JVIR 2016). Follow institutional protocol; routine prophylaxis is not evidence-based for this device
Drainage plan discussion: malignant ascites typically recurs every 10–14 days after LVP — confirm patient is a candidate for self-drainage. Discuss volume limits per session (especially for cirrhotic patients); overly aggressive drainage contributes to renal injury and hyponatremia
3
Relevant Anatomy
Access Site Anatomy
- Standard access site: left lower quadrant, lateral to rectus muscle (avoid inferior epigastric artery within rectus sheath); 3 cm medial and 3 cm superior to ASIS
- Tunnel exit site: 5–8 cm from chest wall incision in a location accessible to patient for self-drainage
Key Danger Structures
- Inferior epigastric artery: within rectus sheath — stay lateral to rectus to avoid this vessel
- Distended bladder: confirm patient has voided or place Foley before access
- Tethered bowel loops: from prior surgery — assess carefully with US before puncture
- Catheter tip position: should be in pelvis (most dependent position for free ascites), typically pointing toward right iliac fossa from left-sided access
4
Technique
Default RadCall approach · share your own below
Supplies
Ultrasound machine + sterile probe cover
PleurX Peritoneal Kit (15.5 Fr)
1% lidocaine with epinephrine
ChloraPrep, sterile drapes
Scalpel (15 blade)
Tunneling trocar
2-0 nylon/prolene suture
Sterile dressing
Steps
1
US Survey
Patient supine. Identify largest free-flowing ascites pocket in LLQ, lateral to rectus. Confirm no bowel in access path with Doppler. Mark entry site (A) and tunnel exit site (B, 5–8 cm cephalad to A, convenient for patient drainage).
2
Prep and Drape
Full sterile prep of LLQ region including both incision sites.
3
Local Anesthesia
Infiltrate access site, tunnel track, and exit site with 1% lidocaine with epinephrine. Allow full effect before incision.
4
Entry Incision
5 mm incision at site A, blunt dissection to peritoneum. Access peritoneal cavity with Seldinger needle under US guidance (real-time). Aspirate to confirm ascites return.
5
Seldinger Access
Advance guidewire, dilate tract with serial dilators. Place peel-away 15.5 Fr introducer.
6
Tunneling
5 mm incision at site B. Tunnel trocar from B → A subcutaneously. Thread catheter through tunnel (B → A). Position velour cuff 1–2 cm inside tunnel from exit site B.
7
Catheter into Peritoneum
Thread catheter tip through peel-away sheath, direct toward pelvis. Peel away sheath. Confirm fluid flows.
8
Secure Catheter
Suture catheter at entry site A. Foam cuff dressing at exit site B.
9
Initial Drainage
Drain 1500–2000 mL initially. Stop if patient feels lightheaded, has abdominal cramping, or develops hypotension.
10
Imaging
Portable X-ray or fluoroscopy to confirm catheter tip position if needed (not mandatory if US-confirmed).
Sign in to view and create community cards
5
Troubleshooting
Problem
Cannot access peritoneum — needle deflects or no fluid returns
Likely cause: Needle off target, omentum obstructing, inadequate fluid volume in chosen pocket, pre-existing adhesions
Next step: Confirm US in real-time with needle in image. Try different US transducer angle. Consider RLQ access if LLQ adhesion suspected. Hydrodissection with saline if fatty omentum obstructing.
Problem
Ascites leaking around catheter at exit site
Likely cause: High-volume ascites under pressure, catheter exit tract not sealed, early post-procedure (tract not mature)
Next step: Apply occlusive dressing (ostomy bag cutout around exit site). Reduce drainage frequency temporarily. If persistent: a figure-of-8 or purse-string suture around exit site. In cirrhotic patients with low albumin and thin skin: always warn about this pre-procedure.
Problem
Catheter stops draining, no fluid despite large ascites on imaging
Likely cause: Fibrin occlusion of catheter holes, omentum wrapping catheter tip, kinking
Next step: Flush catheter with 20 mL saline. Instill alteplase 4 mg in 20 mL NS (dwell 1h, then aspirate). If still not draining and confirmed occlusion: catheter exchange over wire vs catheter removal and re-placement at different site.
Problem
Exit site erythema / fever / abdominal pain
Triage first: exit site cellulitis (superficial) vs. peritonitis (deep). Complication rates of tunneled peritoneal catheter are similar to those of repeated LVP (Ha et al. 2017)
Exit site cellulitis only (no fever, no ascites changes): Wound culture + oral antibiotics + local wound care. Monitor closely. Peritonitis (fever, abdominal pain, cloudy ascites): Sample ascites through catheter — PMN ≥250/mm³ = peritonitis. Hospitalize. IV antibiotics empirically (cefotaxime 2g q8h or equivalent). Catheter removal required if no resolution with antibiotics alone. For cirrhotic SBP: add albumin 1.5 g/kg day 1 and 1 g/kg day 3. Catheter malfunction does not always require removal — tPA instillation should be tried first for occlusion-related dysfunction.
6
Complications
Immediate
- Technical success rate ~100% (Ha et al. 2017) — placement failure is rare with US + fluoroscopy guidance
- Bowel perforation (rare, <0.5%) — US real-time guidance and Doppler interrogation before puncture minimizes risk
- Bleeding from inferior epigastric artery — stay lateral to rectus sheath
- Vasovagal reaction during large-volume drainage
Delayed
- Peritonitis/exit site infection — overall complication rates similar to repeated LVP; most episodes manageable with antibiotics; catheter removal for failed medical management
- Protein and albumin wasting (cachexia) — ongoing drainage removes protein; nutritional monitoring required; dose-dependent with drainage volume and frequency
- Electrolyte abnormalities — hyponatremia, hypokalemia; more pronounced with high-frequency large-volume drainage
- Catheter occlusion (5–15%) — tPA (alteplase 4 mg in 20 mL NS, dwell 1h) effective; does not require catheter removal as first response
- Ascites leak at exit site — especially in cirrhotic patients with low albumin and high ascites pressure; warn pre-procedure
- Cellulitis at exit site — superficial; oral antibiotics + local care
7
Post-Procedure Care
Immediate Monitoring
- Vital signs post-procedure recovery × 1h
- Discharge home same day if stable
- Drain volume log: record volume removed at each session
- Labs: BMP, albumin at 2–4 weeks, then monthly
Signs of Peritonitis (Patient Education)
- Fever, rigors
- Increased abdominal pain
- Cloudy or unusual-appearing ascites
- → Report immediately to provider
Home Drainage Protocol
- Drain 1000–2000 mL per session (cirrhotic patients: limit to 1–1.5 L/session to prevent acute kidney injury from rapid fluid shift)
- Frequency: every 1–3 days based on symptom burden and drainage volume
- WARNING — cirrhotic patients: aggressive drainage without albumin monitoring contributes to AKI, hyponatremia, and hepatorenal syndrome; counsel explicitly; involve palliative care and hepatology
- Home drainage is safe: confirmed reduction in paracentesis and diuretic requirements without adverse effects on kidney function, serum albumin, or serum sodium (Solbach 2017)
- Significant reduction in ED visits, admissions, and hospital days after catheter vs. period before (Qu et al. 2016)
Protein Monitoring
- Monthly albumin and total protein
- If albumin <2.5 g/dL or total protein <4 g/dL: reduce drainage frequency, increase oral protein intake, coordinate with palliative/primary care
8
Critical Pearls
✶
Malignant vs cirrhotic ascites: Malignant ascites — drain as needed, palliative; protein loss less concerning. Cirrhotic refractory ascites — drain cautiously (1–1.5 L/session), always monitor renal function and albumin; this is palliative in terminal liver disease and must be framed as comfort, not cure.
✶
Albumin monitoring is mandatory for cirrhotic patients: Persistent high-volume drainage without albumin monitoring causes progressive hypoalbuminemia and hepatorenal syndrome. Monthly labs minimum.
✶
SBP prophylaxis in cirrhosis: Norfloxacin 400 mg/day or trimethoprim–sulfamethoxazole double-strength daily is reasonable SBP prophylaxis for cirrhotic patients with indwelling peritoneal catheters. Discuss with hepatology.
✶
Cuff placement: Velour cuff must be 1–2 cm inside subcutaneous tunnel from exit site. If placed outside the skin, infection and catheter extrusion are nearly certain.
✶
Exit site leakage in cirrhosis: Cirrhotic patients have low albumin → poor wound healing + high ascites pressure → high leakage risk. Warn prominently; provide ostomy supplies at discharge.
✶
tPA for occlusion — try before replacing: Catheter malfunction does NOT require removal as first response. Instill alteplase 4 mg in 20 mL NS, dwell 1h, aspirate. Can be done in clinic or home health setting.
✶
Cost-effectiveness threshold: Tunneled peritoneal catheter becomes less costly than repeated LVP after approximately 9–10 paracenteses (assuming 5 L/session every 10 days; Medicare rates, Bohn and Ray 2015). Offer TPC to any patient with expected disease prognosis and >9–10 planned paracenteses.
✶
Intraperitoneal chemotherapy is feasible through the catheter: Tunneled peritoneal catheter can safely be used for IP chemo instillation — no difference in infection rate compared with drainage-only use (Ha et al. 2017). Discuss with oncology for eligible ovarian/peritoneal malignancy patients.
9
References & Resources
Key Guidelines
- AASLD Cirrhosis Guidelines (2021)
- ESMO Clinical Practice Guidelines: Malignant Ascites
- SIR Standards of Practice
Primary References
- Ha T, Madoff DC, Li D. Symptomatic fluid drainage: tunneled peritoneal and pleural catheters. Semin Intervent Radiol. 2017;34:337–342. [Source for indications, complication rates, home drainage safety, IP chemo, cost-effectiveness]
- Barnett TD, Rubins J. Placement of a permanent tunneled peritoneal drainage catheter for palliation of malignant ascites. J Vasc Interv Radiol. 2002;13:379–383.
- Solbach P, et al. Home-based drainage of refractory ascites by a permanent-tunneled peritoneal catheter can safely replace large-volume paracentesis. Eur J Gastroenterol Hepatol. 2017;29:539–546.
- Qu C, et al. The impact of tunneled catheters for ascites and peritoneal carcinomatosis on patient rehospitalizations. Cardiovasc Intervent Radiol. 2016;39:711–716.
- Bohn KA, Ray CE Jr. Repeat large-volume paracentesis versus tunneled peritoneal catheter placement: a cost-minimization study. AJR. 2015;205:1126–1134. [Cost-effective after ~9–10 LVPs]
- Rashid S, et al. Utility of prophylactic antibiotics in tunneled peritoneal and pleural drainage catheters. J Vasc Interv Radiol. 2016;27.
- Becker G, et al. Malignant ascites: systematic review and guideline for treatment. Eur J Cancer. 2006;42:589–597.